Article by GeoVax Labs CEO Featured in October 15 Issue of Genetic Engineering & Biotechnology News
ATLANTA, Oct. 18 /PRNewswire/ — Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).
In the article, titled “Search for Effective HIV Vaccine Intensifies: Progress to Date Result of Robust Funding and Cooperation Between Many Agencies,” Dr. McNally reviews a set of significant advances that spotlight the current state of the HIV vaccine search. These include the finding, based on a Phase 3 trial known as RV144 and publicized by the US Military HIV Research Program, that a combination of two vaccines based on HIV strains that commonly circulate in Thailand was safe and modestly effective in preventing HIV infections. He also notes a report from the NIAID Vaccine Research Center on the discovery of three human antibodies that neutralize HIV, two of which were shown to target a broad range of HIV strains.
“The search for an HIV vaccine is an ongoing research goal that continues to challenge the top minds in the infectious disease research community. Continued funding is vital, and cooperation among various agencies may play an important role,” writes Dr. McNally in the article. “As Seth Berkley and Alan Bernstein–who are president and CEO of the International AIDS Vaccine Initiative and executive director of the Global HIV Vaccine Enterprise, respectively–wrote in The New York Times in July: ‘Ending HIV/AIDS urgently requires a vaccine. The evidence that a safe and effective HIV vaccine can be developed is stronger than ever.’”
To access the full text of the article, please click on the following link:
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines’ safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax’s Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Earlier this year, patient enrollment began in a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit http://www.geovax.com.
Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax’s filings with the Securities and Exchange Commission including those set forth at “Risk Factors” in GeoVax’s Form 10-K.
SOURCE GeoVax Labs, Inc.